
Beroceutica reinvents healthcare with Artificial Intelligence. It identifies significant patterns in clinical datasets, which can be used for novel diagnostics and therapies. Beroceutica's technology monitors individual responses to drug action, using a selection of 'hot-spot' SNPs, as well as non-genetic markers. It uses machine learning algorithms like artificial neural networks to stratify patients in clinical studies. Drug actions are simulated along the biochemical pathways. The company also discovers novel, synergistic drug combinations to overcome currently unmet medical needs.

Beroceutica reinvents healthcare with Artificial Intelligence. It identifies significant patterns in clinical datasets, which can be used for novel diagnostics and therapies. Beroceutica's technology monitors individual responses to drug action, using a selection of 'hot-spot' SNPs, as well as non-genetic markers. It uses machine learning algorithms like artificial neural networks to stratify patients in clinical studies. Drug actions are simulated along the biochemical pathways. The company also discovers novel, synergistic drug combinations to overcome currently unmet medical needs.
Company: Beroceutica
Core focus: AI for clinical data to identify diagnostics, therapies and drug combinations
Founders mentioned: Joern Klinger; Marco Schmidt
Funding (records searched): No funding rounds found on searched databases
Translational bioinformatics / computational drug discovery and personalized medicine
Healthcare / Biotechnology
Total Funding: 0.00 USD